<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Algorithm</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Ultromics' Echogo improves cardiac amyloidosis diagnosis</title>
      <description>
        <![CDATA[A month after raising $55 million to advance its AI-enhanced ultrasound diagnostics for cardiovascular disease, Ultromics Ltd. presented strong results for its U.S. FDA-cleared AI analysis of echocardiograms at the American Society of Echocardiography's 2025 Scientific Sessions in Nashville, Tenn. Ultromics' Echogo Amyloidosis was able to detect cardiac amyloidosis earlier and more accurately than traditional methods, missing fewer cases without increasing unnecessary testing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724253</guid>
      <pubDate>Fri, 26 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724253-ultromics-echogo-improves-cardiac-amyloidosis-diagnosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Ultromics-22nov24.webp?t=1732312800" type="image/jpeg" medium="image" fileSize="383952">
        <media:title type="plain">Ultromics</media:title>
      </media:content>
    </item>
    <item>
      <title>Phyxiom looks to transform outcomes for patients with asthma, COPD</title>
      <description>
        <![CDATA[Recently launched Irish startup Phyxiom Ltd. hopes that its digital health platform will transform the clinical outcomes for patients with asthma and chronic obstructive pulmonary disease. By providing clinicians with real-time insights into lung function and medication adherence, the platform improves diagnosis accuracy and treatment outcomes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723448</guid>
      <pubDate>Thu, 28 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723448-phyxiom-looks-to-transform-outcomes-for-patients-with-asthma-copd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/respiratory-lung-COPD.webp?t=1589292813" type="image/png" medium="image" fileSize="244662">
        <media:title type="plain">Lungs and bronchiole </media:title>
      </media:content>
    </item>
    <item>
      <title>Aktiia SA raises $42M for BP monitoring platform, rebrands to Hilo</title>
      <description>
        <![CDATA[Aktiia SA raised $42 million in an oversubscribed series B funding round and rebranded to Hilo. The funds will be used for product innovation, expansion into new markets and to build out its blood pressure monitoring platform to support enterprise use cases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719633</guid>
      <pubDate>Tue, 06 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719633-aktiia-sa-raises-42m-for-bp-monitoring-platform-rebrands-to-hilo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Hilo-Band-and-App-6may25.webp?t=1746564203" type="image/jpeg" medium="image" fileSize="106462">
        <media:title type="plain">Hilo Band and mobile app</media:title>
        <media:description type="plain">Hilo Band and mobile app. Credit: Hilo</media:description>
      </media:content>
    </item>
    <item>
      <title>AI helps UK doctors identify patients at risk of afib</title>
      <description>
        <![CDATA[An artificial intelligence-based tool developed by researchers in the U.K. is helping doctors identify people at risk of developing atrial fibrillation. Data from the ongoing Find-AF pilot study shows that the algorithm can comb through patients’ electronic health records and detect red flags which could indicate whether they are at risk of developing the heart condition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715580</guid>
      <pubDate>Tue, 31 Dec 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715580-ai-helps-uk-doctors-identify-patients-at-risk-of-afib</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Atrial-fibrillation-illustration.webp?t=1620156165" type="image/png" medium="image" fileSize="398365">
        <media:title type="plain">Atrial fibrillation illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Myriad’s test reduces gene-drug interactions, hospitalizations nearly 40%</title>
      <description>
        <![CDATA[Finding an effective medication for patients with major depressive disorder is notoriously difficult, with 70% of patients failing to respond to the first drug prescribed and 30% not responding to the first four medications. Complicating matters, genetic mutations can increase psychotropic drug-related adverse events, including hospitalizations. A recent study indicates Myriad Genetics Inc.’s Genesight test can help minimize the risk of these negative events, with a reduction of nearly 40% in psychiatric-related hospitalizations and prescription of medications with significant gene-drug interactions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707158</guid>
      <pubDate>Thu, 11 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707158-myriads-test-reduces-gene-drug-interactions-hospitalizations-nearly-40</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Gene-drug-interaction-11apr24.webp?t=1712870684" type="image/jpeg" medium="image" fileSize="33623">
        <media:title type="plain">Gene drug interaction</media:title>
        <media:description type="plain">Example of combinatorial impact of genetic variability of drug X based on Myriad Genetics’ Genesight test. Credit: Myriad Genetics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Proteins on the move (briefly) offer targeting possibilities</title>
      <description>
        <![CDATA[Researchers have identified a druggable pocket on the phosphatase Wip1, which regulates the tumor suppressor TP53 as well as DNA damage repair proteins. The work, which was published in <em>Frontiers in Molecular Biosciences</em> on April 18, 2023, by researchers from the University of Pennsylvania, could lead to therapeutics targeting Wip1. And the computational deep learning methods used to identify the pocket are broadly useful for identifying what the authors call “cryptic” pockets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/696368</guid>
      <pubDate>Tue, 25 Apr 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/696368-proteins-on-the-move-briefly-offer-targeting-possibilities</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Thioredoxin-antioxidant-enzyme.webp?t=1682433922" type="image/png" medium="image" fileSize="535092">
        <media:title type="plain">3D illustration of thioredoxin antioxidant enzyme</media:title>
        <media:description type="plain">Protein structure prediction methods have improved greatly, but are still largely static “snapshots.”</media:description>
      </media:content>
    </item>
    <item>
      <title>‘Guilt by association’ yields new drug targets</title>
      <description>
        <![CDATA[A ‘guilt by association’ study linking disease-associated proteins to proteins for which there was no evidence of any role in pathology, has identified groups of proteins interacting with genes that genome-wide association studies (GWAS) have previously implicated in 21 disease areas. Revealing these interactions has thrown up new drug targets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694629</guid>
      <pubDate>Tue, 28 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694629-guilt-by-association-yields-new-drug-targets</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Open-Targets-Interactome.webp?t=1677600894" type="image/png" medium="image" fileSize="1238720">
        <media:title type="plain">Concept image for interactome finding drug targets</media:title>
        <media:description type="plain">A human interactome to prioritize drug discovery. Credit: Karen Arnott/EMBL-EBI</media:description>
      </media:content>
    </item>
    <item>
      <title>Reflexion inks deal with Mirada to improve personalized cancer treatment</title>
      <description>
        <![CDATA[Reflexion Medical Inc. entered into a nonexclusive worldwide licensing agreement with Mirada Medical Ltd., allowing Mirada’s Redengine image registration algorithms to be integrated into Reflexion’s X1 treatment planning software. The algorithms align a patient’s anatomy between distinct imaging modalities or between radiotherapy treatments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520718</guid>
      <pubDate>Thu, 14 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520718-reflexion-inks-deal-with-mirada-to-improve-personalized-cancer-treatment</link>
    </item>
    <item>
      <title>Physiq and Purdue develop infection-detection watch</title>
      <description>
        <![CDATA[As a counterpoint to the raft of wellness-promoting smartwatches, Purdue University and Physiq Inc. have developed a smartwatch algorithm that flags illness. A year after launching their co-development program, the two organizations reported they have created an algorithm designed for smartwatches that enables detection of early signs of infection. The algorithm is already in use in a number of Physiq’s customers’ applications, Physiq Chief Scientific Officer Stephan Wegerich told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512967</guid>
      <pubDate>Tue, 02 Nov 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512967-physiq-and-purdue-develop-infection-detection-watch</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/11-02-Physiq-smart-watch-Perdue-University.webp?t=1635890599" type="image/png" medium="image" fileSize="389348">
        <media:title type="plain">Man looking at Physiq smartwatch on wrist</media:title>
        <media:description type="plain">Purdue University engineers and Physiq have developed a viral detection algorithm for smartwatches. The technology will be commercialized by Physiq. Credit: Purdue University/John Underwood</media:description>
      </media:content>
    </item>
    <item>
      <title>FTC eyes streamlined enforcement for algorithm bias, drug patents and right to repair</title>
      <description>
        <![CDATA[The U.S. Federal Trade Commission (FTC) has taken a more assertive stance regarding enforcement of several considerations, most conspicuously about mergers and acquisitions. However, the agency’s push for less cumbersome processes has now been applied to a host of considerations pertinent to the life sciences, including bias found in artificial intelligence algorithms, abuse of drug patents, and repairs for medical equipment, a signal that more frequent and more rapid FTC enforcement is on the near horizon.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511439</guid>
      <pubDate>Wed, 15 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511439-ftc-eyes-streamlined-enforcement-for-algorithm-bias-drug-patents-and-right-to-repair</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-silhouette.webp?t=1597864591" type="image/png" medium="image" fileSize="459689">
        <media:title type="plain">AI silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Thaler comes up short in district court fight over inventorship rights for AI</title>
      <description>
        <![CDATA[The question of whether an artificial intelligence (AI) algorithm can be an inventor has been making the rounds in the past couple of years, and the question came up again in the U.S. District Court for the Eastern District of Virginia. Stephen Thaler, who developed the Device for the Autonomous Bootstrapping of Unified Sentience (DABUS) algorithm that has been credited with two inventions, failed to persuade the court that an algorithm qualifies as an “individual,” and thus patents must still be assigned to humans, at least where the U.S. Patent and Trademark Office is concerned.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511163</guid>
      <pubDate>Tue, 07 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511163-thaler-comes-up-short-in-district-court-fight-over-inventorship-rights-for-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-as-filament-in-light-bulb.webp?t=1695304772" type="image/jpeg" medium="image" fileSize="168302">
        <media:title type="plain">Brain as light bulb filament</media:title>
      </media:content>
    </item>
    <item>
      <title>Opsens deal will integrate diagnostic algorithms with Cathmedical’s hemodynamic system</title>
      <description>
        <![CDATA[TORONTO &ndash; Opsens Inc. has inked an agreement with Madrid, Spain&rsquo;s Cathmedical Cardiovascular SA to integrate its coronary physiology algorithms with the Spanish firm&rsquo;s next generation hemodynamic system, notably Opsens&rsquo; diastolic pressure ratio (DPR) for measuring diastolic heart pressure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/506537</guid>
      <pubDate>Thu, 29 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/506537-opsens-deal-will-integrate-diagnostic-algorithms-with-cathmedicals-hemodynamic-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardiology-heart-illustration.webp?t=1601070099" type="image/png" medium="image" fileSize="948393">
        <media:title type="plain">Colorful illustration of the heart</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA regulation of AI complicated by hospital’s use of in-house algorithms</title>
      <description>
        <![CDATA[The authors of a recent journal article see problems with the FDA&rsquo;s approach to premarket review of artificial intelligence (AI) algorithms, including an undue reliance on single-site algorithm development. Regulatory attorney Brad Thompson told <em>BioWorld</em>, however, that hospital administrators want algorithms that maximize accuracy for their populations and are not averse to in-house development of just such an algorithm, thus creating a source of tension between what hospitals want and what the FDA expects.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505755</guid>
      <pubDate>Fri, 09 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505755-fda-regulation-of-ai-complicated-by-hospitals-use-of-in-house-algorithms</link>
    </item>
    <item>
      <title>Tiger Tech snares first EUA for machine learning algorithm applied to COVID-19 screening</title>
      <description>
        <![CDATA[The COVID-19 pandemic has affected wide swaths of the global economy, mostly in a negative manner, but it has spurred some types of innovation at a rate that would be unimaginable in ordinary times. That seems to be the take-away for an emergency use authorization (EUA) granted to Miami-based Tiger Tech Solutions Inc. for its COVID Plus monitor, which uses plethysmography and a machine learning algorithm to provide a screening mechanism at mass gatherings, thus bringing the world one step closer to a state of normalcy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505021</guid>
      <pubDate>Mon, 22 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505021-tiger-tech-snares-first-eua-for-machine-learning-algorithm-applied-to-covid-19-screening</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/covid-19-coronavirus-US-digital.webp?t=1745260939" type="image/jpeg" medium="image" fileSize="476752">
        <media:title type="plain">Digital illustration of U.S., coronavirus</media:title>
      </media:content>
    </item>
    <item>
      <title>Empatica wins CE mark for wearable-based early symptoms detection of COVID-19</title>
      <description>
        <![CDATA[MIT Media Labs spinoff Empatica Inc. secured the CE mark for its Aura system, a wearable solution for the monitoring and early alert of respiratory infections, including COVID-19. For use with people 14 and older, Aura is commercially available in Europe and the U.K., and for pilot purposes in the U.S. &ndash; pending FDA authorization. Aura&rsquo;s algorithm analyzes vital signs from Empatica smartwatches, comparing data against the wearer&rsquo;s historical baselines. In validation studies, Aura was able to detect patients with possible H1N1 influenza, rhinovirus or SARS-CoV-2 infection with 0.94 sensitivity. Detection occurred on average two days after infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504608</guid>
      <pubDate>Wed, 10 Mar 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504608-empatica-wins-ce-mark-for-wearable-based-early-symptoms-detection-of-covid-19</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/03-10-Empatica-Aura.webp?t=1615414310" type="image/png" medium="image" fileSize="1706064">
        <media:title type="plain">Smartwatch on wrist next to smartphone with Empatica Care app on screen</media:title>
        <media:description type="plain">Aura is the first wearable solution to be CE marked for the early detection of COVID-19. Credit: Empatica Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Alivecor gains clearance for AI-driven personal ECG</title>
      <description>
        <![CDATA[The U.S. FDA cleared Alivecor Inc.&#39;s Kardia AI V2 interpretive electrocardiogram (ECG) algorithm for use in its personal ECG app and devices. Currently, the Kardia line permits consumers to take a 30-second medical grade ECG at home and instantly see whether they are exhibiting symptoms of atrial fibrillation, bradycardia, tachycardia or have normal heart rhythm.]]>
      </description>
      <guid>http://www.bioworld.com/articles/500543</guid>
      <pubDate>Mon, 23 Nov 2020 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/500543-alivecor-gains-clearance-for-ai-driven-personal-ecg</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/11-23-Alivecor-KardiaMobile-6L.webp?t=1606169861" type="image/png" medium="image" fileSize="620623">
        <media:title type="plain">Close up of person using Kardiamobile 6L</media:title>
        <media:description type="plain">Kardiamobile 6L. Credit: Alivecor Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Berkeley Lights flies high with $178M IPO, while Renalytix AI raises $74M</title>
      <description>
        <![CDATA[Med-tech IPOs continue to make it out onto a strong stock market, even as global economic uncertainty prevails amidst the unfolding pandemic. Single-cell biology research company Berkeley Lights Inc. priced an upsized IPO to raise $178.2 million to back its tools that are used to help develop antibody therapeutics, cell therapies and, more broadly, synthetic biology products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/455849</guid>
      <pubDate>Fri, 17 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/455849-berkeley-lights-flies-high-with-178m-ipo-while-renalytix-ai-raises-74m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/AI-digital-dollar-coins.webp?t=1588782231" type="image/png" medium="image" fileSize="299797">
        <media:title type="plain">Wireframe hands, coins</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA gives breakthrough nod to Dascena’s predictive algorithm for acute kidney injury</title>
      <description>
        <![CDATA[Machine learning-based diagnostics startup Dascena Inc. has won the U.S. FDA&rsquo;s breakthrough device designation for its Previse algorithm, which is designed to predict acute kidney injury (AKI) before clinical symptoms. In early validation tests, Previse detected AKI more than a day before patients exhibited kidney damage or impaired function.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436299</guid>
      <pubDate>Tue, 07 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436299-fda-gives-breakthrough-nod-to-dascenas-predictive-algorithm-for-acute-kidney-injury</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/Kidney-dialysis-AI.webp?t=1589217904" type="image/png" medium="image" fileSize="203534">
        <media:title type="plain">Kidney illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>AI-focused Owkin rakes in an additional $18M to series A</title>
      <description>
        <![CDATA[LONDON &ndash; Owkin Inc. added a further $18 million to its series A, bringing the amount raised in the round to $70 million and equipping the company to push forward with its federated learning approach to applying artificial intelligence (AI) to the analysis of health data.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436240</guid>
      <pubDate>Thu, 02 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436240-ai-focused-owkin-rakes-in-an-additional-18m-to-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-network-machine-learning.webp?t=1588275771" type="image/png" medium="image" fileSize="504733">
        <media:title type="plain">Ribbons of digital data</media:title>
      </media:content>
    </item>
    <item>
      <title>Evidation scoops up $45M in series D to help expand the reach of Achievement into virtual health</title>
      <description>
        <![CDATA[Evidation Health Inc. reported good news this week in the form of the close of $45 million in series D funding, with an eye toward the expansion of its research platform, Achievement, to include virtual health. B Capital Group led the round, with Mckesson Ventures and Section 32 joining, in addition to existing investors Revelation Partners, Rethink Impact and SV Health Investors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436190</guid>
      <pubDate>Wed, 01 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436190-evidation-scoops-up-45m-in-series-d-to-help-expand-the-reach-of-achievement-into-virtual-health</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/AI-digital-dollar-coins.webp?t=1588782231" type="image/png" medium="image" fileSize="299797">
        <media:title type="plain">Wireframe hands, coins</media:title>
      </media:content>
    </item>
    <item>
      <title>Radiology research alliance adds algorithm for reliable blood flow data via 3D ultrasound</title>
      <description>
        <![CDATA[Researchers working as part of the Quantitative Imaging Biomarkers Alliance (QIBA) have recently validated an open-source algorithm that can be used to measure blood flow using existing 3D ultrasound technology from major manufacturers. They published their results in the June 30, 2020, issue of <em>Radiology</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436187</guid>
      <pubDate>Wed, 01 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436187-radiology-research-alliance-adds-algorithm-for-reliable-blood-flow-data-via-3d-ultrasound</link>
    </item>
    <item>
      <title>Brightinsight gets $40M series B to supply the back-end of digital health for pharma, med tech</title>
      <description>
        <![CDATA[Startup Brightinsight Inc. is working to make the infrastructure behind digital health easily accessible to pharma and med-tech companies. To aid it on this path, the San Jose, Calif.-based company has raised a $40 million series B round to expand its capabilities and global reach.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436065</guid>
      <pubDate>Thu, 25 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436065-brightinsight-gets-40m-series-b-to-supply-the-back-end-of-digital-health-for-pharma-med-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/AI-digital-dollar-coins.webp?t=1588782231" type="image/png" medium="image" fileSize="299797">
        <media:title type="plain">Wireframe hands, coins</media:title>
      </media:content>
    </item>
    <item>
      <title>Wave Guard’s algorithm-based solution aims to aid in contact tracing</title>
      <description>
        <![CDATA[HONG KONG &ndash; Contact tracing is seen as one of the more effective measures to contain the current COVID-19 pandemic. Now, an Israeli company may hold the solution with its app-free tech. Herzliya-based Wave Guard Technologies Inc. has an algorithm-based solution that allows government health care agencies to trace contacts of COVID-19-infected individuals accurately, effectively and in real time.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435148</guid>
      <pubDate>Fri, 15 May 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435148-wave-guards-algorithm-based-solution-aims-to-aid-in-contact-tracing</link>
    </item>
    <item>
      <title>Eko scores EUA for algorithm to identify heart failure in COVID-19 patients</title>
      <description>
        <![CDATA[The U.S. FDA has given the greenlight to Eko Devices Inc.&rsquo;s electrocardiogram (ECG)-based algorithm to aid in detecting patients with heart failure during the COVID-19 pandemic. The artificial intelligence (AI)-powered algorithm, which provides a quick way to screen for low ejection fraction, won FDA breakthrough status in December of 2019.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435086</guid>
      <pubDate>Wed, 13 May 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435086-eko-scores-eua-for-algorithm-to-identify-heart-failure-in-covid-19-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/5-13-EKO-screening.webp?t=1589412709" type="image/png" medium="image" fileSize="1935966">
        <media:title type="plain">Eko device and software in use during in-clinic screening</media:title>
        <media:description type="plain">The Duo ECG device offers AI-powered decision support.
Credit: Eko Devices Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Australian researchers develop AI algorithm that uses 3D scans to predict sleep apnea</title>
      <description>
        <![CDATA[ERTH, Australia &ndash; A recent study conducted at the University of Western Australia (UWA) Centre for Sleep Science shows that facial features analyzed from 3D photographs could predict the likelihood of having obstructive sleep apnea.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435012</guid>
      <pubDate>Mon, 11 May 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435012-australian-researchers-develop-ai-algorithm-that-uses-3d-scans-to-predict-sleep-apnea</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/5-11-sleep-apnea-3D-analysis.webp?t=1589231253" type="image/png" medium="image" fileSize="648039">
        <media:title type="plain">Points of measurement in 3D head scan</media:title>
        <media:description type="plain">Facial features analyzed from 3D photographs could 
predict the likelihood of having obstructive sleep apnea
Credit: Journal of Clinical Sleep Medicine</media:description>
      </media:content>
    </item>
    <item>
      <title>Health Canada accelerates approval of AI-driven COVID-19 tool</title>
      <description>
        <![CDATA[TORONTO &ndash; Within a week of completing clinical trials the chest radiography AI tool developed by Vancouver, B.C.-based 1Qbit Inc. has been given the all-clear from Health Canada for deployment across the country. The XrAI was originally developed to better identify patients with respiratory illness including SARS, pneumonia and tuberculosis (TB), but then in February was tested on a publicly available data set of COVID-19 X-ray images.]]>
      </description>
      <guid>http://www.bioworld.com/articles/434777</guid>
      <pubDate>Thu, 30 Apr 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/434777-health-canada-accelerates-approval-of-ai-driven-covid-19-tool</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/4-30-1QBit-xrAI-Chest-X-ray-Abnormal.webp?t=1588283694" type="image/png" medium="image" fileSize="265557">
        <media:title type="plain">4-30-1QBit-xrAI-Chest-X-ray-Abnormal.png</media:title>
        <media:description type="plain">The XrAI tool detects pulmonary abnormalities 
in chest X-rays. Credit: 1Qbit Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Behold.ai secures 510(k) for Red Dot image recognition algorithm</title>
      <description>
        <![CDATA[LONDON &ndash; Behold.ai Ltd. has secured U.S. FDA 510(k) approval for use of its Red Dot image recognition algorithm in the automatic diagnosis of life-threatening pneumothorax (collapsed lung). The product completes the analysis immediately, sending an alert to the radiologist as soon as an X-ray is taken. &ldquo;It does in 30 seconds what would normally take up to 30 minutes,&rdquo; said Simon Rasalingham, CEO of London-based Behold.ai.]]>
      </description>
      <guid>http://www.bioworld.com/articles/433775</guid>
      <pubDate>Tue, 17 Mar 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/433775-beholdai-secures-510k-for-red-dot-image-recognition-algorithm</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-17-BeholdAI-red-dot.webp?t=1584479173" type="image/png" medium="image" fileSize="613647">
        <media:title type="plain">3-17-BeholdAI-red-dot.png</media:title>
        <media:description type="plain">Red dot algorithm. Credit: Behold.ai Ltd.  </media:description>
      </media:content>
    </item>
    <item>
      <title>Nantomics’ deep learning algorithm provides fast identification of cancer marker</title>
      <description>
        <![CDATA[Nantomics LLC, of Culver City, Calif., reported that research based on the company&rsquo;s deep learning system has been published in a peer-reviewed journal, highlighting the algorithm&rsquo;s ability to discern which mutation drives a patient&rsquo;s breast cancer. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/433181</guid>
      <pubDate>Thu, 20 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433181-nantomics-deep-learning-algorithm-provides-fast-identification-of-cancer-marker</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells-pic.webp?t=1591653278" type="image/png" medium="image" fileSize="432362">
        <media:title type="plain">Digital cancer cells illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Nantomics’ deep learning algorithm provides fast identification of cancer marker</title>
      <description>
        <![CDATA[Nantomics LLC, of Culver City, Calif., reported that research based on the company&rsquo;s deep learning system has been published in a peer-reviewed journal, highlighting the algorithm&rsquo;s ability to discern which mutation drives a patient&rsquo;s breast cancer. The company said their approach is a rapid and cost-effective way to establish the breast cancer subtype, thus giving clinician and patient alike a good understanding of which therapies would be ineffective for that cancer and maximizing the chances for a cure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/433170</guid>
      <pubDate>Wed, 19 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433170-nantomics-deep-learning-algorithm-provides-fast-identification-of-cancer-marker</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells-pic.webp?t=1591653278" type="image/png" medium="image" fileSize="432362">
        <media:title type="plain">Digital cancer cells illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Orpyx unveils sensory insoles to better predict dangerous diabetic foot ulcers</title>
      <description>
        <![CDATA[TORONTO &ndash; Calgary, Alberta-based Orpyx Medical Technologies Inc. has launched a sensory insole with remote patient monitoring to prevent potentially fatal diabetic foot ulcers (DFU) and neuropathy-related ulcers. According to Orpyx CEO Breanne Everett, development of the Orpyx SI sensory insole system follows years of study on how DFUs occur and how best to share information with patients and doctors so they can react quickly to first signs of the condition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432737</guid>
      <pubDate>Fri, 31 Jan 2020 11:30:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432737-orpyx-unveils-sensory-insoles-to-better-predict-dangerous-diabetic-foot-ulcers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-30-Orpyx-insole.webp?t=1580420109" type="image/png" medium="image" fileSize="570275">
        <media:title type="plain">1-30-Orpyx-insole.png</media:title>
        <media:description type="plain">Sensory Insoles. Credit: Orpyx Medical Technologies Inc.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
